Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Резистентная vs неконтролируемая артериальная гипертензия: тактика назначения антигипертензивной терапии
Резистентная vs неконтролируемая артериальная гипертензия: тактика назначения антигипертензивной терапии
Адашева Т.В., Задионченко В.С., Федорова И.В., Шахрай Н.Б. Резистентная vs неконтролируемая артериальная гипертензия: тактика назначения антигипертензивной терапии. Consilium Medicum. 2017; 19 (5): 20–25.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзорной статье представлен анализ основных причин резистентности к антигипертензивной терапии и неконтролируемой артериальной гипертензии. Обсуждается тактика подбора комбинированной антигипертензивной терапии. Рассматриваются преимущества 3-компонентной комбинированной терапии, включающей антагонист кальция амлодипин, ингибитор ангиотензинпревращающего фермента периндоприл и тиазидоподобный диуретик индапамид. Приводится анализ исследований, показывающих эффективность и безопасность фиксированной комбинации амлодипин/индапамид/периндоприл.
Ключевые слова: резистентная артериальная гипертензия, фиксированные комбинации, периндоприл, амлдодипин, индапамид.
Key words: resistant arterial hypertension, fixed dose combination, perindopril, amlodipine, indapamide.
Ключевые слова: резистентная артериальная гипертензия, фиксированные комбинации, периндоприл, амлдодипин, индапамид.
________________________________________________
Key words: resistant arterial hypertension, fixed dose combination, perindopril, amlodipine, indapamide.
Полный текст
Список литературы
1. Mancia G, Fagard R, Narkiewicz K et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2013 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2013; 31 (7): 1281–357.
2. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009; 27: 2121–58.
3. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
4. Чазова И.Е. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
5. Оганов Р.Г. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваск. терапия и профилактика. 2011; 10 (1): 9–13. / Oganov R.G. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
6. Chow CK, Teo KK, Rangarajan S et al. PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
7. Frohlich ED. Classification of resistant hypertension. Hypertension 1988; 11: 1167–70.
8. Mazzaglia G, Mantovani LG, Sturkenboom MC et al. Pattern of persistence with antihypertensive medication in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093–100.
9. Garg JP, Elliot WJ, Folker A et al. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5): 619–26.
10. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353: 487–97.
11. Thoenes M, Neuberger H-R, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24: 336–44.
12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents, a meta-analysis. Hypertension 2010; 55: 399–407.
13. Johnoston CI, Fabris B, Yamada T. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertension Suppl 1989; 7 (5): S11–7.
14. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747–803.
15. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction: results of a substudy of the EUROPA study PERTINENT. Cardiovasc Res 2007; 73: 237–46.
16. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression [from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE) Study]. Am J Cardiol 2007; 100: 159–63.
17. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2methylindoline antihypertensive diuretic. Am Heart J 1983; 106 (1, Pt 2): 208–11.
18. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
19. Marre M, Puig JG, Kokot F еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
20. Асташкин Е.И., Глезер М.Г., Петров Е.А. Влияние индапамида на уровень радикалов кислорода, продуцируемых фагоцитами крови пациентов с сердечной недостаточностью. Рос. кардиол. журн. 2012; 4: 43–7. / Astashkin E.I., Glezer M.G., Petrov E.A. Vliianie indapamida na uroven' radikalov kisloroda, produtsiruemykh fagotsitami krovi patsientov s serdechnoi nedostatochnost'iu. Ros. kardiol. zhurn. 2012; 4: 43–7. [in Russian]
21. Hernaґndez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409–14.
22. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34 (3): 869–77.
23. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168 (2): 239–44.
24. BHS-NICE. Guidelines. Clinical management of primary hypertension in adults 2011. Updated April 2016. http://www.nice.org.uk
25. Toth K. PIANIST Investigators. Antihypertensive efficacy of triple combination plus amlodipine in risk hypertensive patients. Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
26. Páll D, SzántóI, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
27. Efficiency of the combined treatment of arterial hypertension in Ukraine: results of the TRIUMF multicenter study M.I.Lutay, on behalf of the TRIUMF multicenter study group. Український кардіол. журн. 2016; 4: 17–28.
2. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009; 27: 2121–58.
3. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
4. Chazova I.E. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
5. Oganov R.G. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
6. Chow CK, Teo KK, Rangarajan S et al. PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
7. Frohlich ED. Classification of resistant hypertension. Hypertension 1988; 11: 1167–70.
8. Mazzaglia G, Mantovani LG, Sturkenboom MC et al. Pattern of persistence with antihypertensive medication in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093–100.
9. Garg JP, Elliot WJ, Folker A et al. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5): 619–26.
10. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353: 487–97.
11. Thoenes M, Neuberger H-R, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24: 336–44.
12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents, a meta-analysis. Hypertension 2010; 55: 399–407.
13. Johnoston CI, Fabris B, Yamada T. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertension Suppl 1989; 7 (5): S11–7.
14. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747–803.
15. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction: results of a substudy of the EUROPA study PERTINENT. Cardiovasc Res 2007; 73: 237–46.
16. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression [from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE) Study]. Am J Cardiol 2007; 100: 159–63.
17. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2methylindoline antihypertensive diuretic. Am Heart J 1983; 106 (1, Pt 2): 208–11.
18. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
19. Marre M, Puig JG, Kokot F еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
20. Astashkin E.I., Glezer M.G., Petrov E.A. Vliianie indapamida na uroven' radikalov kisloroda, produtsiruemykh fagotsitami krovi patsientov s serdechnoi nedostatochnost'iu. Ros. kardiol. zhurn. 2012; 4: 43–7. [in Russian]
21. Hernaґndez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409–14.
22. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34 (3): 869–77.
23. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168 (2): 239–44.
24. BHS-NICE. Guidelines. Clinical management of primary hypertension in adults 2011. Updated April 2016. http://www.nice.org.uk
25. Toth K. PIANIST Investigators. Antihypertensive efficacy of triple combination plus amlodipine in risk hypertensive patients. Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
26. Páll D, SzántóI, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
27. Efficiency of the combined treatment of arterial hypertension in Ukraine: results of the TRIUMF multicenter study M.I.Lutay, on behalf of the TRIUMF multicenter study group. Український кардіол. журн. 2016; 4: 17–28.
2. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009; 27: 2121–58.
3. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
4. Чазова И.Е. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
5. Оганов Р.Г. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваск. терапия и профилактика. 2011; 10 (1): 9–13. / Oganov R.G. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
6. Chow CK, Teo KK, Rangarajan S et al. PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
7. Frohlich ED. Classification of resistant hypertension. Hypertension 1988; 11: 1167–70.
8. Mazzaglia G, Mantovani LG, Sturkenboom MC et al. Pattern of persistence with antihypertensive medication in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093–100.
9. Garg JP, Elliot WJ, Folker A et al. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5): 619–26.
10. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353: 487–97.
11. Thoenes M, Neuberger H-R, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24: 336–44.
12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents, a meta-analysis. Hypertension 2010; 55: 399–407.
13. Johnoston CI, Fabris B, Yamada T. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertension Suppl 1989; 7 (5): S11–7.
14. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747–803.
15. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction: results of a substudy of the EUROPA study PERTINENT. Cardiovasc Res 2007; 73: 237–46.
16. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression [from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE) Study]. Am J Cardiol 2007; 100: 159–63.
17. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2methylindoline antihypertensive diuretic. Am Heart J 1983; 106 (1, Pt 2): 208–11.
18. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
19. Marre M, Puig JG, Kokot F еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
20. Асташкин Е.И., Глезер М.Г., Петров Е.А. Влияние индапамида на уровень радикалов кислорода, продуцируемых фагоцитами крови пациентов с сердечной недостаточностью. Рос. кардиол. журн. 2012; 4: 43–7. / Astashkin E.I., Glezer M.G., Petrov E.A. Vliianie indapamida na uroven' radikalov kisloroda, produtsiruemykh fagotsitami krovi patsientov s serdechnoi nedostatochnost'iu. Ros. kardiol. zhurn. 2012; 4: 43–7. [in Russian]
21. Hernaґndez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409–14.
22. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34 (3): 869–77.
23. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168 (2): 239–44.
24. BHS-NICE. Guidelines. Clinical management of primary hypertension in adults 2011. Updated April 2016. http://www.nice.org.uk
25. Toth K. PIANIST Investigators. Antihypertensive efficacy of triple combination plus amlodipine in risk hypertensive patients. Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
26. Páll D, SzántóI, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
27. Efficiency of the combined treatment of arterial hypertension in Ukraine: results of the TRIUMF multicenter study M.I.Lutay, on behalf of the TRIUMF multicenter study group. Український кардіол. журн. 2016; 4: 17–28.
________________________________________________
2. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009; 27: 2121–58.
3. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
4. Chazova I.E. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
5. Oganov R.G. i dr. Epidemiologiia arterial'noi gipertonii v Rossii. Rezul'taty federal'nogo monitoringa 2003–2010 gg. Kardiovask. terapiia i profilaktika. 2011; 10 (1): 9–13. [in Russian]
6. Chow CK, Teo KK, Rangarajan S et al. PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
7. Frohlich ED. Classification of resistant hypertension. Hypertension 1988; 11: 1167–70.
8. Mazzaglia G, Mantovani LG, Sturkenboom MC et al. Pattern of persistence with antihypertensive medication in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093–100.
9. Garg JP, Elliot WJ, Folker A et al. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5): 619–26.
10. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353: 487–97.
11. Thoenes M, Neuberger H-R, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24: 336–44.
12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents, a meta-analysis. Hypertension 2010; 55: 399–407.
13. Johnoston CI, Fabris B, Yamada T. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertension Suppl 1989; 7 (5): S11–7.
14. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747–803.
15. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction: results of a substudy of the EUROPA study PERTINENT. Cardiovasc Res 2007; 73: 237–46.
16. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression [from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE) Study]. Am J Cardiol 2007; 100: 159–63.
17. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2methylindoline antihypertensive diuretic. Am Heart J 1983; 106 (1, Pt 2): 208–11.
18. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
19. Marre M, Puig JG, Kokot F еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
20. Astashkin E.I., Glezer M.G., Petrov E.A. Vliianie indapamida na uroven' radikalov kisloroda, produtsiruemykh fagotsitami krovi patsientov s serdechnoi nedostatochnost'iu. Ros. kardiol. zhurn. 2012; 4: 43–7. [in Russian]
21. Hernaґndez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10 (6): 409–14.
22. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34 (3): 869–77.
23. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168 (2): 239–44.
24. BHS-NICE. Guidelines. Clinical management of primary hypertension in adults 2011. Updated April 2016. http://www.nice.org.uk
25. Toth K. PIANIST Investigators. Antihypertensive efficacy of triple combination plus amlodipine in risk hypertensive patients. Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
26. Páll D, SzántóI, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34: 701–8.
27. Efficiency of the combined treatment of arterial hypertension in Ukraine: results of the TRIUMF multicenter study M.I.Lutay, on behalf of the TRIUMF multicenter study group. Український кардіол. журн. 2016; 4: 17–28.
Авторы
Т.В.Адашева*, В.С.Задионченко, И.В.Федорова, Н.Б.Шахрай
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*adashtv@mail.ru
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*adashtv@mail.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*adashtv@mail.ru
________________________________________________
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*adashtv@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.